Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:53:26.301Z.
Calculation as of: 2026-10-06T19:53:26.301Z.
Quote observation: 2026-10-06T19:50:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6b8b16bed2a6fff21aaa666e30465ae2bcbbc8377d0ad77d6381797994f17b37
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$106.98M
EV/EBIT Ratio
N/A
TTM Avg
56.93x
3Y Avg
94.02x
5Y Avg
53.96x
Market Cap
$106.44M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.20M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.37M
EV/EBIT Ratio
0.64x
TTM Avg
0.59x
3Y Avg
0.59x
5Y Avg
0.59x
Market Cap
$109.12M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | $107.00M | N/A | N/A | N/A | N/A |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | N/A | 56.93x | 94.02x | 53.96x |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.44M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $106.59M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $108.43M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.20M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.37M | 0.64x | 0.59x | 0.59x | 0.59x |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.12M | N/A | N/A | N/A | N/A |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.18M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
